WAVE Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Recommendation of “Moderate Buy” by Analysts

WAVE Life Sciences Ltd. (NASDAQ:WVE) has earned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and fourteen have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $32.5625.

A number of equities research analysts have recently commented on the stock. UBS Group set a $32.00 price target on shares of WAVE Life Sciences in a report on Tuesday, December 16th. B. Riley Financial increased their target price on WAVE Life Sciences from $19.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Cantor Fitzgerald boosted their price target on WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Canaccord Genuity Group upped their price target on WAVE Life Sciences from $40.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, February 3rd. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of WAVE Life Sciences in a research report on Monday, December 8th.

Insider Buying and Selling at WAVE Life Sciences

In other WAVE Life Sciences news, insider Chandra Vargeese sold 3,228 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $13.45, for a total value of $43,416.60. Following the transaction, the insider owned 408,246 shares in the company, valued at $5,490,908.70. The trade was a 0.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Plc Gsk bought 1,470,000 shares of the stock in a transaction dated Thursday, December 11th. The shares were acquired at an average price of $19.00 per share, with a total value of $27,930,000.00. Following the completion of the purchase, the insider directly owned 18,245,691 shares of the company’s stock, valued at approximately $346,668,129. This represents a 8.76% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders sold 915,181 shares of company stock worth $13,612,581. 23.98% of the stock is currently owned by insiders.

Institutional Investors Weigh In On WAVE Life Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in WVE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of WAVE Life Sciences by 9.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,349 shares of the company’s stock valued at $463,000 after purchasing an additional 4,957 shares during the period. Goldman Sachs Group Inc. raised its position in WAVE Life Sciences by 3.8% in the first quarter. Goldman Sachs Group Inc. now owns 557,644 shares of the company’s stock worth $4,506,000 after acquiring an additional 20,624 shares in the last quarter. TD Asset Management Inc raised its position in WAVE Life Sciences by 16.3% in the second quarter. TD Asset Management Inc now owns 179,608 shares of the company’s stock worth $1,167,000 after acquiring an additional 25,200 shares in the last quarter. Privium Fund Management B.V. lifted its holdings in WAVE Life Sciences by 19.4% in the 2nd quarter. Privium Fund Management B.V. now owns 135,550 shares of the company’s stock valued at $884,000 after acquiring an additional 22,000 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its position in shares of WAVE Life Sciences by 8.2% during the 2nd quarter. Teacher Retirement System of Texas now owns 28,955 shares of the company’s stock valued at $188,000 after purchasing an additional 2,206 shares in the last quarter. Institutional investors own 89.73% of the company’s stock.

WAVE Life Sciences Price Performance

Shares of NASDAQ:WVE opened at $13.49 on Monday. WAVE Life Sciences has a 12 month low of $5.28 and a 12 month high of $21.73. The firm has a market capitalization of $2.26 billion, a price-to-earnings ratio of -17.99 and a beta of -1.78. The business’s 50 day simple moving average is $14.63 and its 200-day simple moving average is $10.61.

WAVE Life Sciences Company Profile

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.